TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05626114: A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degenera

Sponsor: Genentech, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,058,400

Rescue Site Savings

+$1,361,200

Unlock Full NCT05626114 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05626114 Rescue Dossier →